The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.
Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
Those who are expected to need insulin prescription during the study period.
Patients with type 2 diabetes scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone
Cohort
Prospective
Not listed
Percentage of subjects who correspond to high risk score (≥8) by evaluating simple NAFLD score
Click on the lead sponsor to view all of their trials.
